PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-139.60%
Negative net income growth indicates shrinking profitability. Benjamin Graham would label it a concern unless explained by temporary factors.
0.49%
D&A up to 5% yoy – Manageable. Seth Klarman would see normal expansions if revenue justifies the extra depreciation.
No Data
No Data available this quarter, please select a different quarter.
637.66%
SBC above 30% yoy – Very high. Philip Fisher would demand major growth or breakthroughs to justify such heavy share-based payments.
-41.30%
A negative yoy change in working capital can free up cash. Benjamin Graham would confirm it is not from falling demand or asset disposal.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-41.30%
A negative yoy shift in other WC might free up cash flow. Benjamin Graham would confirm the items are not essential to operations or revenue generation.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Negative yoy CFO growth indicates a decline in core cash generation. Benjamin Graham would treat it as a serious warning unless cyclical factors explain it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Issuance above 15% yoy – Significant equity raise. Philip Fisher would require a very compelling reason to risk heavy shareholder dilution.
No Data
No Data available this quarter, please select a different quarter.